MARCHESELLI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.089
AS - Asia 8.742
EU - Europa 8.351
SA - Sud America 1.113
OC - Oceania 542
AF - Africa 414
Continente sconosciuto - Info sul continente non disponibili 13
Totale 37.264
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.461
GB - Regno Unito 2.959
SG - Singapore 1.953
CN - Cina 1.680
IT - Italia 1.121
HK - Hong Kong 910
VN - Vietnam 866
DE - Germania 843
BR - Brasile 790
SE - Svezia 632
PH - Filippine 552
AU - Australia 496
TR - Turchia 469
FI - Finlandia 446
CA - Canada 441
FR - Francia 437
RU - Federazione Russa 340
UA - Ucraina 287
IR - Iran 286
IN - India 285
KR - Corea 207
PK - Pakistan 190
ID - Indonesia 161
JP - Giappone 150
NL - Olanda 141
IE - Irlanda 139
BG - Bulgaria 119
MY - Malesia 118
BD - Bangladesh 116
ES - Italia 116
PL - Polonia 116
ZA - Sudafrica 113
AR - Argentina 108
GR - Grecia 99
MX - Messico 98
SA - Arabia Saudita 93
IQ - Iraq 87
IL - Israele 85
TW - Taiwan 85
MA - Marocco 77
BE - Belgio 71
AT - Austria 64
TH - Thailandia 59
AE - Emirati Arabi Uniti 57
NP - Nepal 55
EC - Ecuador 50
RO - Romania 49
LK - Sri Lanka 45
NZ - Nuova Zelanda 45
CO - Colombia 44
KE - Kenya 44
NO - Norvegia 44
JO - Giordania 43
GE - Georgia 39
EG - Egitto 38
CH - Svizzera 35
LT - Lituania 33
LV - Lettonia 32
CL - Cile 30
CZ - Repubblica Ceca 30
EE - Estonia 28
PT - Portogallo 28
HR - Croazia 25
NG - Nigeria 23
VE - Venezuela 22
BA - Bosnia-Erzegovina 21
TN - Tunisia 21
UZ - Uzbekistan 21
HU - Ungheria 20
PE - Perù 18
SI - Slovenia 18
DZ - Algeria 17
OM - Oman 17
PY - Paraguay 17
SK - Slovacchia (Repubblica Slovacca) 17
BO - Bolivia 14
BZ - Belize 14
UG - Uganda 14
UY - Uruguay 13
BH - Bahrain 12
LB - Libano 12
AZ - Azerbaigian 11
CY - Cipro 10
DK - Danimarca 10
DO - Repubblica Dominicana 10
ET - Etiopia 10
PR - Porto Rico 10
MU - Mauritius 9
PA - Panama 9
PS - Palestinian Territory 9
CR - Costa Rica 8
KZ - Kazakistan 8
QA - Qatar 8
JM - Giamaica 7
LY - Libia 7
A2 - ???statistics.table.value.countryCode.A2??? 6
GH - Ghana 6
GY - Guiana 6
KG - Kirghizistan 6
MO - Macao, regione amministrativa speciale della Cina 6
Totale 37.127
Salva come PNG Salva come JPEG
Città #
Fairfield 1.815
Ashburn 1.687
Southend 1.619
Santa Clara 1.335
Singapore 1.232
Woodbridge 1.143
Chandler 839
Houston 827
Hong Kong 811
Seattle 686
Wilmington 658
Cambridge 591
Jacksonville 505
San Jose 485
Dearborn 428
Ann Arbor 404
Nyköping 401
Beijing 375
Hefei 370
London 339
Helsinki 332
Los Angeles 304
Ho Chi Minh City 275
Chicago 265
New York 237
Hanoi 229
Modena 228
Frankfurt am Main 224
Council Bluffs 214
Redwood City 183
Munich 180
San Diego 178
The Dalles 163
Izmir 154
Seoul 129
Shanghai 120
Princeton 116
Sofia 113
Salt Lake City 111
Melbourne 106
Dallas 105
Milan 100
Eugene 96
Moscow 94
Lauterbourg 88
Jakarta 81
São Paulo 81
Dublin 76
Manchester 76
Sydney 76
Tokyo 74
Buffalo 73
Istanbul 71
Ottawa 61
Bremen 59
Brisbane 59
Bologna 53
Elk Grove Village 53
Warsaw 53
Columbus 52
Phoenix 50
Tampa 47
Falls Church 46
Paris 46
Taipei 46
Athens 43
Liverpool 43
Johannesburg 42
Da Nang 41
Brussels 40
Montreal 40
Quezon City 39
Casablanca 38
Des Moines 38
Tehran 38
Fremont 37
Orem 36
Toronto 36
Colombo 35
Karachi 35
Lahore 35
Riyadh 35
Denver 34
Dong Ket 34
Islamabad 34
Kuala Lumpur 34
Stockholm 34
Cebu City 32
Manila 32
Perth 32
Amsterdam 31
Birmingham 31
Boston 31
Brooklyn 31
Amman 30
Atlanta 30
Davao City 30
Rio de Janeiro 30
Rome 30
Nairobi 29
Totale 23.347
Salva come PNG Salva come JPEG
Nome #
Empathy and burnout: an analytic cross-sectional study among nurses and nursing students 6.887
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 680
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 620
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 609
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 514
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 510
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 484
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 467
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 427
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 401
The impact of shift work on the psychological and physical health of nurses in a general hospital: a comparison between rotating night shifts and day shifts 401
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 398
Identification of protein clusters predictive of response to chemotherapy in breast cancer patients 387
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 377
N,N-DIMETHYLFORMAMIDE-2-METHOXYETHANOL SOLVENT SYSTEM - DENSITIES AND EXCESS MOLAR VOLUMES AT VARIOUS TEMPERATURES 376
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 372
Incidence, clinical features and possible etiology of early onset (≤40 years) colorectal neoplasms. 367
The outcome of peripheral t-cell lymphoma patients failing first-line therapy: A report from the prospective, international t-cell project 363
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 361
Empathic attitudes among nursing students: a preliminary study 360
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 359
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 359
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 354
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 349
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 348
A NON-LINEAR CORRELATION MODEL FOR THE RELATIVE PERMITTIVITY OF TERNARY AMPHIPROTIC (SOLVENT) MIXTURES 344
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 342
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 331
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 330
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 329
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network 320
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 318
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study 310
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 309
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 307
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 306
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 302
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 300
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 300
ANALYSIS OF HEAVY-METALS IN ACETO-BALSAMICO-TRADIZIONALE-DI-MODENA BY FLAME ATOMIC-ABSORPTION SPECTROSCOPY 299
Cancer incidence, mortality, and survival in Eastern Libya: Updated report from the Benghazi Cancer Registry 299
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 297
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 297
2-methoxyethanol - water solvent system : static relative permittivity from -10 to 80°C 296
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 296
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 296
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 294
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis 293
Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: A population-based study 292
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 292
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 287
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 285
Prognostic relevance of microsatellite instability in pT3N0M0 colon cancer: a population-based study 284
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 282
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 280
Multicentre validation of an immune-inflammation-based nomogram to predict survival in western resectable gastroesophageal adenocarcinoma: The NOMOGAST 279
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 277
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 277
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 277
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi 276
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 276
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL) 274
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi 274
Estimating survival in newly diagnosed cancer patients: use of computer simulations to evaluate performances of different approaches in a wide range of scenarios. 273
Durability and efficacy of tibial arterial stent placement for critical limb ischemia 270
Watchful waiting in low-tumorburden follicular lymphoma in the Rituximab era. Results of a F2 observational 269
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 268
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi 268
Dielectric properties of ethane-1,2-diol + 2-methoxyethanol + water liquid ternary mixtures 267
CLIPI: a new prognostic index for indolent cutaneos B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 262
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 261
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 259
Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. 247
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 247
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 244
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 241
The relative permittivity of the ternary 1,2-ethanediol + 2-methoxyethanol + water solvent system 239
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 234
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. 233
Twenty-years experience with de novo metastatic breast cancer 231
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 231
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 228
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 227
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 222
Contemporary economic and clinical evaluations of endovascular repair for intact descending thoracic aortic aneurysms 219
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 218
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 217
Standard “off-the-shelf” multibranched thoracoabdominal endograft in urgent and elective patients with single and staged procedures in a multicenter experience 215
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 211
I tumori nelle provincie di Parma, Reggio Emilia, Modena 210
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. 200
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) 197
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma 189
Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi. 188
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma 187
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas 186
The Relative Permittivity of N,N-Dimethylformamide/1,2-Dimethoxyethane Binary Mixtures from -10 to 40 C 184
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study 184
Influence of Thoracic Endovascular Repair on Aortic Morphology in Patients Treated for Blunt Traumatic Aortic Injuries: Long Term Outcomes in a Multicentre Study 182
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 178
Totale 36.843
Salva come PNG Salva come JPEG
Categoria #
all - tutte 118.775
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 118.775
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021621 0 0 0 0 0 0 0 0 0 0 371 250
2021/20223.136 194 240 388 194 143 218 170 207 338 260 489 295
2022/20233.279 285 357 233 328 359 401 144 304 390 151 180 147
2023/20243.220 111 149 218 250 622 263 469 377 110 180 218 253
2024/20255.924 195 113 193 476 1.102 779 476 436 680 269 502 703
2025/20269.254 658 424 690 1.193 1.679 785 1.181 522 959 975 188 0
Totale 37.676